Simplex Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-129,600
Closed -$393K 10007
2024
Q4
$393K Buy
129,600
+82,600
+176% +$360K ﹤0.01% 3797
2024
Q3
$243K Sell
47,000
-35,000
-43% -$174K ﹤0.01% 4327
2024
Q2
$210K Buy
82,000
+5,800
+8% +$19.8K ﹤0.01% 4604
2024
Q1
$374K Buy
76,200
+18,600
+32% +$110K ﹤0.01% 4150
2023
Q4
$506K Buy
57,600
+15,600
+37% +$128K ﹤0.01% 3691
2023
Q3
$481K Buy
42,000
+25,700
+158% +$494K ﹤0.01% 3444
2023
Q2
$412K Buy
16,300
+1,100
+7% +$34.3K ﹤0.01% 3515
2023
Q1
$489K Sell
15,200
-30,400
-67% -$948K ﹤0.01% 3289
2022
Q4
$841K Sell
45,600
-22,500
-33% -$515K ﹤0.01% 2645
2022
Q3
$1.84M Buy
68,100
+26,900
+65% +$546K ﹤0.01% 2039
2022
Q2
$569K Sell
41,200
-47,800
-54% -$736K ﹤0.01% 3287
2022
Q1
$1.74M Buy
89,000
+77,400
+667% +$1.17M ﹤0.01% 2254
2021
Q4
$189K Buy
11,600
+10,800
+1,350% +$180K ﹤0.01% 5286
2021
Q3
$24K Buy
800
+100
+14% +$2.85K ﹤0.01% 8294
2021
Q2
$20K Buy
700
+688
+5,733% +$19.8K ﹤0.01% 8602
2021
Q1
$33K Sell
12
-122
-91% -$3.37K ﹤0.01% 7049
2020
Q4
$379K Buy
134
+98
+272% +$2.54K ﹤0.01% 3793
2020
Q3
$90K Buy
36
+6
+20% +$157 ﹤0.01% 5026
2020
Q2
$73K Sell
30
-3
-9% -$59 ﹤0.01% 5135
2020
Q1
$48K Sell
33
-84
-72% -$1.74K ﹤0.01% 5175
2019
Q4
$189K Buy
117
+13
+13% +$202 ﹤0.01% 3832
2019
Q3
$135K Hold
104
﹤0.01% 3982
2019
Q2
$134K Buy
104
+84
+420% +$1.06K ﹤0.01% 3889
2019
Q1
$31K Buy
+20
New +$347 ﹤0.01% 5397
2018
Q4
Sell
-6
Closed -$14K 7974
2018
Q3
$14K Sell
6
-7
-54% -$190 ﹤0.01% 6246
2018
Q2
$35K Sell
13
-15
-54% -$451 ﹤0.01% 5420
2018
Q1
$4K Buy
28
+2
+8% +$64 ﹤0.01% 4863
2017
Q4
$1K Buy
+26
New +$747 ﹤0.01% 5679
2016
Q3
Sell
-43
Closed -$5K 6587
2016
Q2
$5K Buy
+43
New +$760 ﹤0.01% 4295
2016
Q1
Sell
-81
Closed -$101K 6394
2015
Q4
$101K Buy
81
+79
+3,950% +$2.74K 0.01% 1357
2015
Q3
$3K Buy
+2
New +$61 ﹤0.01% 4444

Other funds holding RVNC

Simplex Trading's RVNC Position: Q1 2025 in Review

Simplex Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 38,598 shares — an estimated $117K sold.

Simplex Trading first reported a position in RVNC in Q3 2015 and held it in 25 quarters. The position peaked at $1.28M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Simplex Trading reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Simplex Trading sold 38,598 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $117K.
  • Simplex Trading first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 25 quarters.
  • Simplex Trading's Revance Therapeutics, Inc. position peaked at $1.28M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Simplex Trading's 13F filing for Q1 2025, filed 12 May 2025.